Clinical trials: Idiopathic Parkinsons Disease
Idiopathic Parkinson's Disease
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home…
- Trial name
- CARE-ACT (NCT01330290)
- Testing
- Neupro®
- Where
- 54 sites in Germany
- Volunteers
- 148 people
- Sponsor
- UCB Pharma
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease
Light treatment was originally employed in Parkinson's disease (PD) to determine if it might be effective in treating co-existing symptoms of depression and insomnia.
- Trial name
- NCT02175472
- Testing
- Spectramax light therapy device, Control light device
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 92 people
- Sponsor
- PhotoPharmics, Inc.
Advanced Idiopathic Parkinson's Disease
Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
The primary objective of this study is to collect health economic data depicting the initial levels and natural progression over time of resource usage, Parkinson's disease (PD)-related costs, and health related quality of life…
- Trial name
- DAPHNE (NCT00141518)
- Testing
- Levodopa-carbidopa intestinal gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, percutaneous endoscopic gastrostomy tube (PEG tube)
- Volunteers
- 77 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Parkinson's Disease
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's…
- Trial name
- NCT00593606
- Testing
- Rotigotine
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Advanced Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease
- Trial name
- NCT00501969
- Testing
- Rotigotine
- Where
- 53 sites in Australia, Austria and 15 more
- Volunteers
- 395 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
The primary objective of this study is to evaluate the perception of pain associated with Parkinson´s Disease in patients who receive Neupro® for the first time.
- Trial name
- NEUPAD (NCT01606670)
- Where
- 27 sites in Austria, Germany
- Volunteers
- 93 people
- Sponsor
- UCB Pharma GmbH
Orthostatic Hypotension, Idiopathic Parkinson Disease
Lundbeck TOMs Orthostatic Hypotension
Orthostatic hypotension (OH), which consists in a significant reduction in blood pressure levels upon standing from a seated position, may affect approximately one in three patients with Parkinson's disease (PD).
- Trial name
- NCT04510922
- Testing
- Droxidopa 100 MG [Northera]
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alberto Espay, MD, MSc
Parkinson's Disease
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease.
- Trial name
- NCT00519532
- Testing
- Rotigotine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson's Disease
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.
- Trial name
- NCT01300819
- Testing
- Rotigotine
- Where
- 87 sites in Austria, Belgium and 10 more
- Volunteers
- 349 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple doses of PF-06669571 in subjects with idiopathic Parkinson's disease.
- Trial name
- NCT02565628
- Testing
- PF-06669571
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec
Early Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
- Trial name
- NCT00599196
- Testing
- Rotigotine
- Where
- 63 sites in Australia, Austria and 18 more
- Volunteers
- 381 people
- Sponsor
- UCB Pharma
Advanced Idiopathic Parkinson's Disease
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with…
- Trial name
- REFRESH-PD (NCT01519882)
- Testing
- Rotigotine
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- UCB Pharma SA
Parkinson's Disease
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.
- Trial name
- NCT02462603
- Testing
- PTC-589
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Edison Pharmaceuticals Inc
Advanced Idiopathic Parkinson's Disease
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
The purpose of this study is to assess the safety and feasibility of switching subjects with advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess the effects of Rotigotine on motor and…
- Trial name
- NCT01711866
- Testing
- Rotigotine
- Where
- 21 sites in United States, Malaysia and 3 more
- Volunteers
- 87 people
- Sponsor
- UCB BIOSCIENCES GmbH